Killian Meara

Genentech said it’s sharing the data with global health authorities to make the therapy available to patients as soon as possible.

For National Recovery Month, Drug Topics sat down with Jake Nichols, PharmD, MBA, to discuss what kinds of resources there are for pharmacists dealing with a substance use disorder.

Check out this list of our top 10 stories from September 2024.

Catch up on important immunization news from the month of September.

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.

Check out these featured Drug Topics interviews from September 2024.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

LEO Pharma expects the regulatory review process to be completed in the second half of 2025.

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.

Check out important updates from the FDA for the week of September 16.

Roche announced positive topline results from the phase 3 CENTERSTONE study that evaluated the efficacy of baloxavir marboxil for the reduction of direct flu transmission.

The Eversense 365 is the world’s first long-term CGM that provides 1 year of use and should be available by the fourth quarter of 2024.

The approval was based on data from the phase 3 MANDARA trial, where the therapy met the primary endpoint of proportion of patients in remission at weeks 36 and 48.

The MVA-BN vaccine is manufactured by Bavarian Nordic and has shown strong efficacy against mpox infection in real-world studies.

A study found there were 216 active supportive care clinical trials and that industry sponsors rarely provided funding.

Patients who completed electronic patient-reported outcome measures said they made them feel more involved in their care and better supported.

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

Check out important updates from the FDA for the week of August 9.

Albert Dahan, MD, PhD, professor of anesthesiology at Leiden University Medical Center, talks about the first-in-class dual-NMR agonist cebranopadol.

A recent meta-analysis found that supplementing with vitamin D could improve blood pressure, blood lipid levels, and glycemic parameters.

Viridian Therapeutics also said it has completed enrollment for a second phase 3 trial of veligrotug, THRIVE-2, and expects topline data to be available by the end of this year.

Data from the SWIFT-1 and SWIFT-2 studies were presented by GSK at the European Respiratory Society International Conference.

LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.

Nymalize is an effective alternative to capsule extraction for adult patients with subarachnoid hemorrhage who are unable to swallow capsules.

Check out important updates from the FDA for the week of September 2.

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.

DaylightRX from Big Health is a digital formulation of cognitive behavioral therapy and is available by prescription only.